高危血液恶性肿瘤患者泊沙康唑缓释片预防暴露不足:常规TDM的依据
这项前瞻性两中心队列研究纳入92例接受泊沙康唑缓释片预防的成人高危血液恶性肿瘤患者,共223份血浆浓度。34.5%样本低于0.7 mg/L,53.3%患者至少一次亚治疗浓度;腹泻时浓度显著更低,提示需常规治疗药物监测。
要点
- 泊沙康唑缓释片预防时亚治疗浓度常见,53.3%患者至少一次低于0.7 mg/L。
- 腹泻患者泊沙康唑血浆浓度显著低于无腹泻者。
- 年龄>60岁与亚治疗浓度风险降低相关。
核心结论
- 泊沙康唑缓释片预防期间亚治疗血浆浓度常见,提示需常规TDM以优化给药。
研究设计与样本
- 前瞻性两中心队列研究,2019年8月至2023年5月纳入92例接受泊沙康唑缓释片预防的成人高危血液恶性肿瘤患者。
主要发现
- 共223份泊沙康唑血浆浓度,77份(34.5%)低于0.7 mg/L,49例(53.3%)患者至少一次亚治疗浓度。
- 第7天中位浓度为0.84 mg/L(IQR 0.47-1.16),随时间无显著变化。
- 腹泻患者中位浓度0.74 mg/L(IQR 0.48-1.00)显著低于无腹泻者0.92 mg/L(IQR 0.64-1.40),P=0.007。
- 多因素分析显示年龄>60岁对亚治疗浓度有保护作用。
- 随访期间5例患者(5.4%)发生6例侵袭性真菌病,1例(1.1%)因泊沙康唑相关肝毒性停药。
关键数值与推荐
- 指南建议泊沙康唑稳态血浆浓度高于0.5-0.7 mg/L。
- 本研究将亚治疗浓度定义为<0.7 mg/L。
临床怎么用
- 对接受泊沙康唑缓释片预防的高危血液恶性肿瘤患者,考虑常规TDM以发现亚治疗浓度并优化剂量。
- 腹泻期间应关注泊沙康唑暴露不足风险,必要时加强TDM。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posaconazole prophylaxis is indicated in high-risk patients with haematological malignancies to prevent invasive fungal diseases (IFDs) with guidelines advising steady-state posaconazole plasma concentrations (PPCs) above 0.5-0.7 mg/L. Therapeutic drug monitoring (TDM), however, is not routinely recommended for posaconazole delayed-release tablet (DRT) prophylaxis. OBJECTIVES: To describe PPCs in hospitalized high-risk patients with haematological malignancies treated for AML or undergoing allogeneic haematopoietic cell transplantation receiving posaconazole prophylaxis with posaconazole DRT and factors influencing exposure. PATIENTS AND METHODS: This prospective, two-centre cohort study measured serial PPCs at Days 7, 14 and 21, and during diarrhoea episodes in adult high-risk patients receiving prophylaxis with posaconazole DRT between August 2019 and May 2023. Patients were followed during hospital admission and for 7 days after the last dose of posaconazole or hospital discharge. RESULTS: Ninety-two patients contributed 223 PPCs. Subtherapeutic PPCs (<0.7 mg/L) occurred in 77 (34.5%) samples and 49 (53.3%) patients recorded ≥1 subtherapeutic PPC. The median Day 7 PPC was 0.84 (IQR: 0.47-1.16) mg/L, with no significant changes over time. In patients with diarrhoea compared with no diarrhoea, the median PPC was significantly lower [0.74 (IQR: 0.48-1.00) mg/L versus 0.92 (IQR: 0.64-1.40) mg/L, P = 0.007]. Multivariate analysis identified older age (>60 years) was protective against subtherapeutic PPCs. Six IFDs developed in five patients (5.4%) during follow-up and posaconazole-attributed hepatotoxicity resulted in cessation for one patient (1.1%). CONCLUSIONS: Subtherapeutic PPCs are common during posaconazole DRT prophylaxis, suggesting the need for routine TDM to optimize dosing in those receiving this posaconazole formulation.
引用
- Urbancic KF, Yong MK, Yong K, et al. Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring. J Antimicrob Chemother. 2026. PMID: 42455040. doi:10.1093/jac/dkag233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。